AU2011307494B2 - Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest - Google Patents

Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest Download PDF

Info

Publication number
AU2011307494B2
AU2011307494B2 AU2011307494A AU2011307494A AU2011307494B2 AU 2011307494 B2 AU2011307494 B2 AU 2011307494B2 AU 2011307494 A AU2011307494 A AU 2011307494A AU 2011307494 A AU2011307494 A AU 2011307494A AU 2011307494 B2 AU2011307494 B2 AU 2011307494B2
Authority
AU
Australia
Prior art keywords
prostacyclin
compound
treprostinil
ethyl
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011307494A
Other languages
English (en)
Other versions
AU2011307494A1 (en
Inventor
Par Johansson
Sisse Rye OSTROWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of AU2011307494A1 publication Critical patent/AU2011307494A1/en
Application granted granted Critical
Publication of AU2011307494B2 publication Critical patent/AU2011307494B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2011307494A 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest Ceased AU2011307494B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070427 2010-10-01
DKPA201070427 2010-10-01
PCT/DK2011/050375 WO2012041334A1 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Publications (2)

Publication Number Publication Date
AU2011307494A1 AU2011307494A1 (en) 2013-05-02
AU2011307494B2 true AU2011307494B2 (en) 2015-08-06

Family

ID=44872128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011307494A Ceased AU2011307494B2 (en) 2010-10-01 2011-09-30 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest

Country Status (9)

Country Link
US (1) US20130261177A1 (enExample)
EP (1) EP2622354A1 (enExample)
JP (1) JP2013543491A (enExample)
KR (1) KR20140025303A (enExample)
CN (2) CN103238070B (enExample)
AU (1) AU2011307494B2 (enExample)
BR (1) BR112013007849A2 (enExample)
CA (1) CA2812846A1 (enExample)
WO (1) WO2012041334A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
US20140044797A1 (en) * 2011-04-19 2014-02-13 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
US20150057325A1 (en) * 2012-03-30 2015-02-26 Rigshospitalet Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3068752A1 (en) 2013-11-13 2016-09-21 Cayman Chemical Company Incorporated Amine salts of a prostacyclin analog
EP3215634B1 (en) 2014-11-06 2021-08-04 The Regents of the University of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN107430136A (zh) * 2015-02-03 2017-12-01 科罗拉多州立大学董事会,公司实体 粘弹性分析用于预测大量出血的用途
DK3278112T3 (da) * 2015-03-29 2021-12-13 Endothel Pharma Aps Sammensætning, der omfatter prostacyclin eller analoger deraf, til behandling af akut, kritisk syge patienter
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
US11169142B2 (en) 2016-05-11 2021-11-09 The Regents Of The University Of Colorado, A Body Corporate Viscoelastic analysis in patients with disease associated with cardiovascular system
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
US12105099B2 (en) * 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN114113641B (zh) * 2021-10-28 2023-11-03 中科精瓒(武汉)医疗技术有限公司 一种活化凝血检测试剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075861A2 (en) * 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
AU4405293A (en) * 1992-06-05 1994-01-04 Barbara M. Alving Test for quantitative thrombin time
JPH11322612A (ja) * 1998-03-13 1999-11-24 Toray Ind Inc 肝細胞増殖因子誘引剤
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
EP2063273A1 (en) * 2007-11-21 2009-05-27 Pentapharm GmbH Method for assessing the fibrinogen contribution in coagulation
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
WO2011089152A1 (en) * 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075861A2 (en) * 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VINCENT, J-L., et al., Prostoglandins, Leukotrienes and Medicine, 1986, Vol. 24, pages 87-92 *

Also Published As

Publication number Publication date
CN106038570A (zh) 2016-10-26
CN103238070B (zh) 2016-06-29
EP2622354A1 (en) 2013-08-07
BR112013007849A2 (pt) 2016-06-07
US20130261177A1 (en) 2013-10-03
JP2013543491A (ja) 2013-12-05
KR20140025303A (ko) 2014-03-04
CN103238070A (zh) 2013-08-07
WO2012041334A1 (en) 2012-04-05
CA2812846A1 (en) 2012-04-05
AU2011307494A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
AU2011307494B2 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
US20150057325A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
EP2207537B1 (en) Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alpha-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
Undas et al. Practical aspects of new oral anticoagulant use in atrial fibrillation
JP2012514014A (ja) 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
Wożakowska-Kapłon et al. Oral health status and the occurrence and clinical course of myocardial infarction in hospital phase: a case-control study
JP2014514310A (ja) 毛細血管漏出の予防及び治療のために手術時に投与されるプロスタサイクリン及びその類似体
JP2007298511A (ja) 血小板機能の流動状態下での測定方法および装置
BR112020023943A2 (pt) métodos de tratamento de pacientes em risco de lesão renal e insuficiência renal
Serebruany et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial
ES2898424T3 (es) Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
Bendel et al. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation
WO2012093681A1 (ja) 敗血症治療薬を投与する患者を選択する方法
Weber et al. Time course of systemic and renal plasma prostanoid concentrations and renal function in ovine hyperdynamic sepsis
WO2018166813A1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
CA2614952A1 (en) Method of treating human volume expansion mediated hypertension employing resibufogenin
EP2129378B1 (en) Therapeutic compositions comprising thromboserin or a salt thereof for use in the prevention or treatment of thrombosis in a patient at risk of bleeding
Szczeklik et al. A single dose of aprotinin prevents platelet hyporeactivity after coronary artery bypass graft surgery
EP3070475B1 (en) In vitro diagnostic, prognosis of contrast induced nephropathy
AV Comparison of Antihypertensive Efficacy and Perinatal Safety of Labetalol and Methyldopa in the Treatment of Hypertension in Pregnancy
Tuncay et al. The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
Sahin et al. Clinical Investigations Relationship Between Endothelial Functions
Yildiz et al. A case of rhabdomyolysis and tromboembolic event secondary to fibrate monotherapy
Morales-Loredo et al. A Dual Blocker of Endothelin A/B Receptors Mitigates Hypertension but not Renal Dysfunction 2 in 3
Zhang et al. Effects of obstructive sleep apnea–hypopnea syndrome on serum macrophage inflammatory protein-1α and high-sensitivity c-reactive protein levels and cardiac structure and function in patients with hypertension

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired